Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenaya TherapeuticsTNYA +0.98%32 Pretax Margin % is -3,909.28% as of Jun. 2026. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Tenaya Therapeutics ranks worse than 92.06% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Tenaya Therapeutics Pretax Margin % Related Terms
Tenaya Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Tenaya Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNYA vs KPTI, HUMA, CRBP: Pretax Margin % Comparison
For the Biotechnology subindustry, Tenaya Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenaya Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics (TNYA) has a Pretax Margin % of -3,909.28% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tenaya Therapeutics and its competitors. According to the industry distribution chart, Tenaya Therapeutics ranks #869 out of 944 companies in the Biotechnology industry, placing it in the top 92.1%.
Is Tenaya Therapeutics' Pretax Margin % too high?
Tenaya Therapeutics' current Pretax Margin % is -3,909.28%. Based on the distribution chart, Tenaya Therapeutics ranks #869 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' Pretax Margin % compare to KPTI and HUMA?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #869 out of 944 companies for Pretax Margin %. This places Tenaya Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current Pretax Margin % is -3,909.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current Pretax Margin % of -3,909.28%. The current Pretax Margin % is -3,909.28%. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current Pretax Margin % is -3,909.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score
Get the complete analysis for TNYA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNYA has been successfully added to your 
